Log In
Print
BCIQ
Print
Print this Print this
 

Adenuric, Feburic, Uloric, febuxostat (Adenuric - EU) (TMX-67)

  Manage Alerts
Collapse Summary General Information
Company Teijin Pharma Ltd.
DescriptionNon-purine selective inhibitor of xanthine oxidase
Molecular Target Xanthine oxidase
Mechanism of ActionXanthine oxidase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationHyperuricemia / gout
Indication DetailsManage chronic hyperuricemia in gout patients; Prevent hyperuricemia in patients with hematological malignancies and at risk of tumor lysis syndrome; Treat chronic gout; Treat hyperuricemia in patients with gout; Treat symptomatic hyperuricemia
Regulatory Designation

Partner

Astellas Pharma Inc.; Ipsen Group; Menarini Group; Takeda Pharmaceutical Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today